|
|
Article: Maxygen Signs Interferon Deal With Roche Worth Up To $230M.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Associate Managing Editor
Maxygen Inc. signed a deal with F. Hoffmann-La Roche Ltd. focused on Maxygen's interferon alpha and beta variants portfolio. At this point, Roche has rights to candidates for hepatitis B and C, but if it takes its option on other indications, the deal's value could blossom to more than $230 million.
Simba Gill, Maxygen's president, said the deal came to life through a combination of factors, which is "how the best deals always work."
Redwood City, Calif.-based Maxygen realized "it should be possible to improve alpha interferon products for hepatitis and possibly other areas," Gill said, noting that the company has ...
Related newspaper, magazine, and journal articles:
|
|
Article: Maxygen Enters Into Development Program for Allergy ...
PR Newswire;
July 26, 2000 ;
700+ words
... ... Russell Howard, Ph.D., Maxygen's CEO. "Part of the difficulty ... looking forward to working with Maxygen and applying their breakthrough ... market opportunity," said Maxygen's President, Dr. Simba Gill. Karolinska Institute is the ...
|
|